Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News February 4th 2011

February 4th 2011

Glycosmedia joins the Institute of Life Science Affiliate Scheme
Institute of Life Science (ILS) Affiliate Membership provides early stage businesses with one of the swiftest and most effective ways of developing a relationship with ILS (Editor)

Effects of insulin and oral antidiabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects
OHA and IT achieved adequate glycemic control and the effects on circulating and muscle inflammatory biomarkers were similar, but only OHA improved insulin sensitivity, vascular function and CIMT. These findings in a small sample suggest that the use of OHA provide additional benefits to patients with T2DM (Diabetes/Metabolism Research and Reviews)

Insulin says NO to cardiovascular disease
This review focuses on insulin-initiated PI3K-Akt-eNOS survival signalling, with nitric oxide as an ‘end effector’ delivering cardioprotection in health and disease (Cardiovascular Research)

De Novo Lipogenesis Maintains Vascular Homeostasis through Endothelial Nitric-oxide Synthase (eNOS) Palmitoylation
De novo lipogenesis, an insulin-dependent process driven by the multifunctional enzyme fatty-acid synthase (FAS), maintains endothelial function by targeting endothelial nitric-oxide synthase (eNOS) to the plasma membrane … Insulin induced FAS in endothelial cells freshly isolated from humans, and eNOS palmitoylation was decreased in mice with insulin-deficient or insulin-resistant diabetes (Journal of Biological Chemistry)

Diabetes factsheet
Diabetes affects 25.8 million people 8.3% of the U.S. population (Centers for Disease Control and Prevention)

Associations Between Concentrations of Vitamin D and Concentrations of Insulin, Glucose, and HbA1c Among Adolescents in the United States
Our results support an inverse association between concentrations of vitamin D and insulin primarily in adolescent male subjects (Diabetes Care)

G6PD Up-Regulation Promotes Pancreatic ß-Cell Dysfunction
These data suggest that up-regulation of G6PD in pancreatic ß-cells would induce ß-cell dysregulation through ROS accumulation in the development of type 2 diabetes (Endocrinology)

Primary Prevention and Control of Type 2 Diabetes and Other Non-Communicable Diseases by Healthy Lifestyle Program
Book by (Prof Madhur Dev Bhattarai FRCP Edin)

Tests for Genetic Interactions in Type 1 Diabetes
This is the largest linkage study reported for any disease. Our data indicate there are no major type 1 diabetes subtypes definable by linkage analyses; susceptibility is caused by actions of HLA and an apparently random selection from a large number of modest-effect loci (Diabetes)

Type 2 diabetes risk allele near CENTD2 is associated with decreased glucose-stimulated insulin release
Of the lead variants from 12 novel type 2 diabetes associated loci, CENTD2 significantly associated with increased plasma glucose values and decreased glucose-stimulated insulin release, suggesting that the diabetogenic effect of this locus is mediated through an impaired pancreatic beta cell function (Diabetologia)

Lilly and the Juvenile Diabetes Research Foundation Partner to Fund Regenerative Medicine Research in Type 1 Diabetes
“The goal of this research agreement is to understand how selected cells can be reprogrammed in order to convert them into insulin-producing cells in the body. JDRF (Lilly)

Sanofi-aventis Announces Positive Top-line Lixisenatide Phase III Results
Sanofi-aventis announce that lixisenatide once-daily achieved primary efficacy endpoint and fewer hypoglycemias vs. exenatide twice-daily (Sanofi-aventis)

Categories: News Pre-2012

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

Boehringer IngelheimNapp DiabetesNovo NordiskAstraZeneca

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)About Ascensia Diabetes CareAbbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership